What is the story about?
What's Happening?
Servier has agreed to acquire KER-0193, a potential treatment for Fragile X syndrome (FXS), from Kaerus Bioscience for up to $450 million. KER-0193, an oral small molecule modulator of BK channels, showed positive results in a Phase I trial. The drug has received Orphan Drug and Rare Pediatric Drug designations from the FDA. Servier plans to launch a Phase II clinical trial in 2026 in the U.S. and Europe.
Why It's Important?
FXS is the most common genetic cause of autism spectrum disorder and intellectual disability, with no approved treatments currently available. Servier's acquisition of KER-0193 represents a significant step towards addressing the unmet medical needs of patients with FXS. The drug's development could lead to new therapeutic options for individuals affected by this rare genetic condition.
What's Next?
Servier will prepare for the Phase II clinical trial of KER-0193, aiming to further evaluate its efficacy and safety in FXS patients. The company is committed to expanding its neurology pipeline with assets targeting rare diseases.
AI Generated Content
Do you find this article useful?
